Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Peregrine plunges on bad bavituximab data

21:20 EDT 27 Jun 2013 | SCRIP

Tustin, California-based Peregrine buried its latest bad clinical trial news in the middle of a press release regarding the Phase III trial design for bavituximab plus docetaxel in the second-line treatment of non-small cell lung cancer (NSCLC). The....

Original Article: Peregrine plunges on bad bavituximab data


More From BioPortfolio on "Peregrine plunges on bad bavituximab data"

Search BioPortfolio:

Relevant Topic

Gilotrif (afatinib) · Latest News · Clinical Trials · Research · Drugs · Reports · Corporate
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...


Searches Linking to this Story